Fludarabine
Ganglioneuroblastoma
Beijing BiotechSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Ganglioneuroblastoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan National Cancer Institute (NCI) | Phase 1/2 | CCC |
AZD1775 National Cancer Institute (NCI) | Phase 1/2 | CCC |
Eb-Dtnb-Nk Beijing Biotech | Phase 1/2 | CCC |
Cyclophosphamide Beijing Biotech | Phase 1/2 | CCC |
FILGRASTIM St. Jude Children's Research Hospital | Phase 1 | CC |
gsk1120212 St. Jude Children's Research Hospital | Phase 1 | CC |
Sonidegib St. Jude Children's Research Hospital | Phase 1 | CC |
Ribociclib St. Jude Children's Research Hospital | Phase 1 | CC |
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →